Stock Market Analysis & Comment

Bears ultimately won out, but it was not Semiconductors that suffered, but the Russell 2000 (IWM) instead. I had talked about the Russell 2000 as the bullish play for yesterday, but in the end, it...

Yesterday, we saw the S&P 500 fall by about 60 basis points, while the Nasdaq 100 declined by approximately 85 basis points. Nvidia (NASDAQ:NVDA) was the leading stock, dropping 2.5% after China...

It will be an important week, with finalized third-quarter productivity data on Tuesday, the CPI on Wednesday, the PPI on Thursday, and Import/Export prices on Friday. The CPI is expected to show a...

This could be viewed as the glass half full after the Nasdaq gained over 3% on Friday, but the Semiconductor Index is doing its best not to participate in the festive goodwill. Technicals edge on the...

• CPI inflation, producer prices, and the last batch of earnings will be in focus this week. • Oracle’s accelerating cloud business and bullish market sentiment make it a top pick to buy this week. •...

The Russell 2000 offers a unique mix of high volatility and potential for outsized returns. Despite its wild swings, the index has consistently posted solid long-term returns. Small caps remain an...

As we approach 2025, savvy investors should consider these five cheap stocks with massive upside potential. Each is trading below Fair Value, making them prime candidates for investors seeking high...

The stock market started the day higher, but by the end of the day, it had given back most of its gains, with the S&P 500 finishing down about 19 basis points. We started to see some signs of...

The winners keep on winning. That sums up the horse race for much of this year based on a set of ETFs targeting the main US equity factor risk premiums. Going into the home stretch for 2024, the...

The S&P 500 remains in a bullish trend, though overbought signals suggest a potential pause or correction. Key support levels to monitor on the S&P 500 futures chart are 6053 and 6000 as the...

The two market-leading weight loss/obesity drugs (GLP-1), Zepabound (Eli Lilly (NYSE:LLY)) and Wegovy (Novo Nordisk (NYSE:NVO)), just completed a clinical side-by-side trial. After 72 weeks of...

Yesterday belonged to the Nasdaq. There was a good opening gap and the index kicked on nicely on higher volume accumulation. Technicals are net bullish. Healthy action with no bearish divergences...

The Santa Claus rally is back on the cards potentially, bringing opportunities for investors. Three standout stocks are ready to deliver seasonal gains. Here’s what to watch for as year-end...

The three stocks I plan to discuss in this piece represent compelling value plays for investors seeking robust growth drivers at reasonable prices. Their above-average financial health, as assessed...